Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RARE Ultragenyx Pharmaceutical Inc

盘前交易 07-22 09:27:25 EDT

42.55

-0.23

-0.54%

盘前42.16

-0.39-0.92%

08:49 EDT

最高43.48	最低42.09	成交量60.68万
今开42.91	昨收42.78	日振幅3.25%
总市值38.54亿	流通市值34.35亿	总股本9,057万
成交额2,583万	换手率0.75%	流通股本8,072万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"RARE","market":"US","secType":"STK","nameCN":"Ultragenyx Pharmaceutical Inc","latestPrice":42.55,"timestamp":1721419200000,"preClose":42.78,"halted":0,"volume":606784,"hourTrading":{"tag":"盘前","latestPrice":42.16,"preClose":42.55,"latestTime":"08:49 EDT","volume":150,"amount":6338.8401,"timestamp":1721652554098},"delay":0,"floatShares":80724200,"shares":90569200,"eps":-7.968776,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.23,"latestTime":"07-22 09:27:25 EDT","open":42.91,"high":43.48,"low":42.09,"amount":25831859.179136,"amplitude":0.032492,"askPrice":44,"askSize":61,"bidPrice":41.85,"bidSize":7,"shortable":3,"etf":0,"ttmEps":-7.968776,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721655000000},"adr":0,"listingDate":1391144400000,"adjPreClose":42.55,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":42.16,"preClose":42.55,"latestTime":"08:49 EDT","volume":150,"amount":6338.8401,"timestamp":1721652554098},"postHourTrading":{"tag":"盘后","latestPrice":42.55,"preClose":42.55,"latestTime":"19:38 EDT","volume":17539,"amount":746284.57,"timestamp":1721432292470},"volumeRatio":0.7816363681765625,"impliedVol":0.532,"impliedVolPercentile":0.344},"requestUrl":"/m/hq/s/RARE/wiki","defaultTab":"wiki","newsList":[{"id":"2444430086","title":"Ultragenyx Pharmaceutical Inc.盘中异动 股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2444430086","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444430086?lang=zh_cn&edition=full","pubTime":"2024-06-19 00:19","pubTimestamp":1718727580,"startTime":"0","endTime":"0","summary":"北京时间2024年06月19日00时19分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价大幅下挫5.00%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为0.36%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Nls Pharmaceutics Ltd.涨幅较大，Mustang Bio, Inc.、Nls Pharmaceutics Ltd.、Qualigen Therapeutics, Inc.较为活跃，换手率分别为716.88%、613.37%、394.65%，振幅较大的相关个股有Nls Pharmaceutics Ltd.、Mustang Bio, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026，振幅分别为119.49%、52.69%、49.60%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240619001941af8e1618&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240619001941af8e1618&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2443362088","title":"BUZZ-Ultragenyx Pharma 因股票发行定价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2443362088","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443362088?lang=zh_cn&edition=full","pubTime":"2024-06-14 21:15","pubTimestamp":1718370953,"startTime":"0","endTime":"0","summary":"    6月14日 - ** Ultragenyx Pharmaceutical   在获得股权融资后，股价在盘前下跌 4.9%，报 41 美元。** RARE 股价周四收盘下跌 3.4%，报 43.12 美元，年内跌幅扩大至约 10** 公司将把募集资金净额用于推进后期临床项目，支持全球商业投放活动和临床前项目。** 周二晚些时候，公司和 Mereo BioPharma    公布了治疗成骨不全症患者骨折的药物的最新 II 期数据 。** 根据伦敦证券交易所的数据，Ultragenyx 公司拥有约 8,310 万股流通股，市值约 36 亿美元，自由流通股约 7,950 万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1668664300.SGD","LU1261432733.SGD","LU1032466523.USD","BK4534","BK4550","LU0976567544.SGD","IE00B1XK9C88.USD","LU0170899867.USD","IE0034235188.USD","LU1917777945.USD","BK4207","BK4566","BUZZ","LU0310799852.SGD","BK4139","IE00BBT3K403.USD","LU0211331839.USD","LU0211328371.USD","LU1244550494.USD","LU1363072403.SGD","LU1670627923.USD","SG9999002224.SGD","SG9999002232.USD","LU0496365809.HKD","LU2023250504.SGD","IE00BKVL7J92.USD","LU2552382215.SGD","LU0149725797.USD","LU1496350502.SGD","LU1244550221.USD","LU2552382058.USD","LU0882574139.USD","LU0211326755.USD","BK4533","LU1914381329.SGD","LU1670628061.USD","RARE","IE00B1BXHZ80.USD","LU2552382132.HKD","LU0971096721.USD","IE00B775SV38.USD","LU1496350171.SGD","LU0256863811.USD","IE00B3S45H60.SGD","LU0211327993.USD","LU0320765646.SGD","LU0320765489.SGD","BK4585","LU1267930490.SGD","LU0106831901.USD"],"gpt_icon":0},{"id":"2443685377","title":"BUZZ-Ultragenyx Pharma 发行 3.5 亿美元股票后下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2443685377","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443685377?lang=zh_cn&edition=full","pubTime":"2024-06-13 21:13","pubTimestamp":1718284384,"startTime":"0","endTime":"0","summary":" ** 该公司在周三晚些时候还表示，正在寻求美国食品及药物管理局加速批准  用于治疗A型桑菲利波综合症的药物。** 周二晚些时候，Ultragenyx公司和Mereo BioPharma公司  公布了治疗成骨不全症患者骨折药物的第二阶段新数据 。** 根据伦敦证券交易所的数据，Ultragenyx 的市值约为 37 亿美元** RARE 股价周三上涨 7.8%，将年初至今的跌幅缩小至 6.6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","IE00B3S45H60.SGD","LU0234572021.USD","LU0971096721.USD","LU1244550221.USD","LU0417517546.SGD","LU0882574139.USD","LU0310799852.SGD","IE0034235188.USD","BK4504","IE00B775SV38.USD","IE00B1XK9C88.USD","BK4207","BK4533","IE00BLSP4239.USD","LU0496365809.HKD","LU1261432733.SGD","LU1496350171.SGD","LU2106854487.HKD","IE00BLSP4452.SGD","LU0211331839.USD","LU1914381329.SGD","LU1917777945.USD","RARE","BK4534","LU0106831901.USD","IE00BBT3K403.USD","LU2552382132.HKD","LU1363072403.SGD","LU0320765646.SGD","LU0211326839.USD","LU0211327993.USD","LU0211326755.USD","LU1668664300.SGD","LU1670628061.USD","BK4550","LU2023250504.SGD","LU2552382058.USD","LU2552382215.SGD","LU0208291251.USD","BK4566","BK4581","IE00B1BXHZ80.USD","IE00BKVL7J92.USD","LU0211328371.USD","LU1244550577.SGD","IE00BZ1G4Q59.USD","LU0256863811.USD","IE00BWXC8680.SGD","LU0149725797.USD"],"gpt_icon":0},{"id":"2443564009","title":"Ultragenyx Pharmaceutical Inc.盘中异动 大幅上涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2443564009","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443564009?lang=zh_cn&edition=full","pubTime":"2024-06-13 00:24","pubTimestamp":1718209454,"startTime":"0","endTime":"0","summary":"北京时间2024年06月13日00时24分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价急速拉升5.12%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体涨幅为0.40%。其相关个股中，Cingulate Inc C/Wts 10/12/2026 、Longeveron Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大，Longeveron Inc.、Tonix Pharmaceuticals Holding Corp.、Tracon Pharmaceuticals, Inc.较为活跃，换手率分别为327.09%、112.00%、34.52%，振幅较大的相关个股有Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Longeveron Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026，振幅分别为85.53%、83.04%、76.92%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240613002414af8d34a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240613002414af8d34a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2441787717","title":"Ultragenyx Pharmaceutical Inc.盘中异动 急速拉升5.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2441787717","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441787717?lang=zh_cn&edition=full","pubTime":"2024-06-06 21:31","pubTimestamp":1717680707,"startTime":"0","endTime":"0","summary":"北京时间2024年06月06日21时31分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价急速拉升5.98%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为0.01%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。Mepsevii 适用于儿童和成人患者，用于治疗粘多糖贮积症 VII。消息层面，截至21时31分，《高盛集团上调Ultragenyx Pharmaceutical至买入评级，上调目标价至67美元》资讯为影响Ultragenyx Pharmaceutical Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024060621314895951012&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024060621314895951012&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2440086946","title":"Ultragenyx Pharmaceutical Inc.盘中异动 股价大涨5.12%报40.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2440086946","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440086946?lang=zh_cn&edition=full","pubTime":"2024-06-01 02:20","pubTimestamp":1717179605,"startTime":"0","endTime":"0","summary":"北京时间2024年06月01日02时20分，Ultragenyx Pharmaceutical Inc.股票出现波动，股价大幅上涨5.12%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体涨幅为0.55%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。该信息摘要如下：B of A Securities：维持Ultragenyx Pharmaceutical评级，由买入调整至买入评级, 目标价由83.00美元调整至76.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240601022005aef2d21f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240601022005aef2d21f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2439426967","title":"Ultragenyx Pharmaceutical Inc：Stifel将目标价格从124.00美元上调至127.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2439426967","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439426967?lang=zh_cn&edition=full","pubTime":"2024-05-31 19:07","pubTimestamp":1717153634,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical Inc：Stifel将目标价格从124.00美元上调至127.00美元","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240531190716957f4c81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240531190716957f4c81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE"],"gpt_icon":0},{"id":"2439218937","title":"美国研究综述-Connectone Bancorp、荷美尔食品公司、UMB 金融公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2439218937","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439218937?lang=zh_cn&edition=full","pubTime":"2024-05-31 15:04","pubTimestamp":1717139072,"startTime":"0","endTime":"0","summary":"    路透5月31日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Connectone Bancorp、Hormel Foods 和 UMB Financial。要点              * Connectone Bancorp Inc   ：KBW将其评级从 \"跑赢大盘 \"下调至 \"市场表现\"。* Hancock Whitney Corp   ：KBW将其评级从 \"跑赢大盘 \"上调至 \"跑赢大盘              * 荷美尔食品公司  ：摩根大通将其评级从 \"减持 \"上调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DELL","KSS","LU1429558221.USD","XYL","LU0417517546.SGD","DG","LU1923621640.USD","JWN","OCFC","UMBF","CNOB","LU2360032135.SGD","HTLF","LU2092937221.SGD","MGY","LU2125154935.USD","S","ULTA","COST","MNST","DKNG","PEP","HRL","RARE","VEEV","LU0566484027.USD","LU1585245621.USD","LU2125910336.SGD","DXLG","NTAP","BURL","BBY","SLDB","MBI","SAM","LU1559883803.SGD","SBCF","STZ","BK4139","BK4581","KDP","FL","MDB","VLY","VSAT","HWC","CELH","LU0266013472.USD","TAP","VERA"],"gpt_icon":0},{"id":"2439937197","title":"Ultragenyx Pharmaceutical Inc：贝尔德将目标价从68美元上调至72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2439937197","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439937197?lang=zh_cn&edition=full","pubTime":"2024-05-31 11:36","pubTimestamp":1717126611,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical Inc：贝尔德将目标价从68美元上调至72美元","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405311136529f0898d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405311136529f0898d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE"],"gpt_icon":0},{"id":"2434879310","title":"Ultragenyx Pharmaceutical Inc.2024财年第一财季实现净利润-1.71亿美元，同比减少4.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434879310","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434879310?lang=zh_cn&edition=full","pubTime":"2024-05-12 00:18","pubTimestamp":1715444307,"startTime":"0","endTime":"0","summary":"3月31日，Ultragenyx Pharmaceutical Inc.公布财报，公告显示公司2024财年第一财季净利润为-1.71亿美元，同比减少4.27%；其中营业收入为1.09亿美元，同比增加9.00%，每股基本收益为-2.03美元。机构评级：截至2024年3月31日，当前有21家机构对Ultragenyx Pharmaceutical Inc.目标价做出预测，其中目标均价为89.00美元，其中最低目标价为47.00美元，最高目标价为140.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405120018298af92759&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405120018298af92759&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE"],"gpt_icon":0},{"id":"2432391765","title":"Ultragenyx Pharmaceutical Inc   预计每股亏损1.73美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2432391765","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432391765?lang=zh_cn&edition=full","pubTime":"2024-05-01 05:32","pubTimestamp":1714512730,"startTime":"0","endTime":"0","summary":"   * Ultragenyx Pharmaceutical Inc    将于5月2日公布截至2001年1月1日的业绩报告，预计该公司的季度收入将有所增长。* 根据LSEG的数据，17位分析师的平均预期显示，这家总部位于加利福尼亚州诺瓦托的公司的营收将从去年同期的1.005亿美元增至1.1609亿美元，增幅为15.4%。* LSEG 分析师对 Ultragenyx Pharmaceutical Inc 的平均预期是每股亏损 1.73 美元。* 华尔街对 Ultragenyx Pharmaceutical Inc 的 12 个月目标价中位数为 81.50 美元，高于其上次收盘价 44.02 美元。4月30日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE"],"gpt_icon":0},{"id":"2429945013","title":"Ultragenyx Pharmaceutical(RARE.US)获加拿大皇家银行首次覆盖，给予优于大市评级, 目标价77.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2429945013","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429945013?lang=zh_cn&edition=full","pubTime":"2024-04-22 17:55","pubTimestamp":1713779754,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical(RARE.US)获加拿大皇家银行首次覆盖，给予优于大市评级, 目标价77.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221755578b45aad9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221755578b45aad9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE"],"gpt_icon":0},{"id":"2428532722","title":"Ultragenyx Pharmaceutical Inc.盘中异动 下午盘快速上涨5.11%报44.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428532722","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2428532722?lang=zh_cn&edition=full","pubTime":"2024-04-18 02:46","pubTimestamp":1713379584,"startTime":"0","endTime":"0","summary":"北京时间2024年04月18日02时46分，Ultragenyx Pharmaceutical Inc.股票出现波动，股价急速上涨5.11%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体涨幅为0.79%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。Mepsevii 适用于儿童和成人患者，用于治疗粘多糖贮积症 VII。该信息摘要如下：Wedbush：重申Ultragenyx Pharmaceutical评级，由中性调整至中性评级, 目标价48.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180246247a538279&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180246247a538279&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2427228868","title":"罕见病巨头Ultragenyx(RARE.US)反义寡核苷酸疗法挺进3期临床 剑指天使综合征","url":"https://stock-news.laohu8.com/highlight/detail?id=2427228868","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2427228868?lang=zh_cn&edition=full","pubTime":"2024-04-16 21:10","pubTimestamp":1713273046,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Ultragenyx Pharmaceutical宣布其用于治疗天使综合征的在研疗法GTX-102在1/2期临床试验中获得的最新数据。据介绍，天使综合征是一种由UBE3A基因缺失或突变所造成的神经系统发育障碍疾病，主要疾病特征包括发育迟缓、智力残疾、言语及平衡障碍。2019年，Ultragenyx和GeneTx达成合作，共同开展针对这一疾病的反义寡核苷酸疗法GTX-102的研究。2022年，Ultragenyx宣布完成对GeneTx的收购，预付款数额为7500万美元，GeneTx还有资格获得额外的里程碑付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2427013650","title":"BUZZ-Ultragenyx 因旧有副作用在试验中再次出现而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2427013650","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2427013650?lang=zh_cn&edition=full","pubTime":"2024-04-15 22:09","pubTimestamp":1713190187,"startTime":"0","endTime":"0","summary":" ** 不过，券商补充说，FDA 和其他监管机构没有提出任何问题或要求采取额外行动，这令券商感到鼓舞。** 20家券商中有18家将该股评为 \"买入 \"或更高评级，2家为 \"持有\"；他们的PT中值为82美元** 如果算上本交易日的损失，该股本年累计跌幅约为 8","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139","BUZZ"],"gpt_icon":0},{"id":"2427000685","title":"Ultragenyx Pharmaceutical Inc.盘中异动 早盘大幅下跌7.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427000685","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2427000685?lang=zh_cn&edition=full","pubTime":"2024-04-15 21:31","pubTimestamp":1713187910,"startTime":"0","endTime":"0","summary":"北京时间2024年04月15日21时31分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价快速下挫7.66%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体涨幅为0.77%。其相关个股中，Soligenix, Inc.、Organovo Holdings, Inc.、Longeveron Inc.涨幅较大，Allarity Therapeutics, Inc.、Soligenix, Inc.、Longeveron Inc.较为活跃，换手率分别为591.11%、347.01%、254.45%，振幅较大的相关个股有Organovo Holdings, Inc.、Soligenix, Inc.、Cassava Sciences Inc C/Wts 15/11/2024，振幅分别为28.71%、24.09%、19.37%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404152131508b263f79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404152131508b263f79&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2427737498","title":"Ultragenyx Pharmaceutical Inc.盘中异动 大幅下挫5.13%报48.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427737498","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2427737498?lang=zh_cn&edition=full","pubTime":"2024-04-13 00:19","pubTimestamp":1712938770,"startTime":"0","endTime":"0","summary":"北京时间2024年04月13日00时19分，Ultragenyx Pharmaceutical Inc.股票出现波动，股价急速跳水5.13%。截至发稿，该股报48.10美元/股，成交量18.8758万股，换手率0.23%，振幅4.76%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为1.14%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404130019317a527a28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404130019317a527a28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2425159827","title":"Ultragenyx Pharmaceutical Inc.盘中异动 急速拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2425159827","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2425159827?lang=zh_cn&edition=full","pubTime":"2024-04-06 00:00","pubTimestamp":1712332808,"startTime":"0","endTime":"0","summary":"北京时间2024年04月06日00时00分，Ultragenyx Pharmaceutical Inc.股票出现波动，股价大幅拉升5.08%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体涨幅为1.09%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。Mepsevii 适用于儿童和成人患者，用于治疗粘多糖贮积症 VII。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404060000087a511523&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404060000087a511523&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2424818315","title":"Ultragenyx Pharmaceutical Inc.盘中异动 大幅拉升5.01%报49.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2424818315","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2424818315?lang=zh_cn&edition=full","pubTime":"2024-04-04 22:41","pubTimestamp":1712241708,"startTime":"0","endTime":"0","summary":"北京时间2024年04月04日22时41分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价急速拉升5.01%。截至发稿，该股报49.44美元/股，成交量12.7797万股，换手率0.16%，振幅4.60%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为0.10%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。Mepsevii 适用于儿童和成人患者，用于治疗粘多糖贮积症 VII。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040422414887e7e0ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040422414887e7e0ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2417486874","title":"Ultragenyx Pharmaceutical Inc.盘中异动 早盘快速下跌5.08%报50.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2417486874","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417486874?lang=zh_cn&edition=full","pubTime":"2024-03-05 23:08","pubTimestamp":1709651285,"startTime":"0","endTime":"0","summary":"北京时间2024年03月05日23时08分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价快速下挫5.08%。截至发稿，该股报50.60美元/股，成交量9.002万股，换手率0.11%，振幅4.87%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为1.38%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240305230806861db6f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240305230806861db6f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RARE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ultragenyx.com","stockEarnings":[{"period":"1week","weight":-0.0574},{"period":"1month","weight":0.1371},{"period":"3month","weight":0.0042},{"period":"6month","weight":-0.046},{"period":"1year","weight":-0.0112},{"period":"ytd","weight":-0.1102}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ultragenyx Pharmaceutical Inc.于2010年4月22日成立，是一家处于发展阶段的生物科技企业，公司随后于2011年6月在特拉华州重新注册成立。公司专注于新型产品的鉴定、收购、开发与商业化，该产品主要用于治疗罕见和极罕见的疾病，产品最初目标是用于治疗严重的，令人衰弱的代谢基因类疾病。公司目前用于治疗遗传性包涵体肌病患者的缓释唾液酸正处于临床试验第二阶段，该疾病是一种渐进式的肌肉萎缩疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.014003},{"month":2,"riseRate":0.636364,"avgChangeRate":0.079614},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.047001},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.001553},{"month":5,"riseRate":0.454545,"avgChangeRate":0.043725},{"month":6,"riseRate":0.727273,"avgChangeRate":0.06466},{"month":7,"riseRate":0.454545,"avgChangeRate":0.01762},{"month":8,"riseRate":0.5,"avgChangeRate":0.006387},{"month":9,"riseRate":0.2,"avgChangeRate":-0.064028},{"month":10,"riseRate":0.2,"avgChangeRate":-0.074469},{"month":11,"riseRate":0.5,"avgChangeRate":0.050565},{"month":12,"riseRate":0.7,"avgChangeRate":0.064436}],"exchange":"NASDAQ","name":"Ultragenyx Pharmaceutical Inc","nameEN":"Ultragenyx Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ultragenyx Pharmaceutical Inc(RARE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ultragenyx Pharmaceutical Inc,RARE,Ultragenyx Pharmaceutical Inc股票,Ultragenyx Pharmaceutical Inc股票老虎,Ultragenyx Pharmaceutical Inc股票老虎国际,Ultragenyx Pharmaceutical Inc行情,Ultragenyx Pharmaceutical Inc股票行情,Ultragenyx Pharmaceutical Inc股价,Ultragenyx Pharmaceutical Inc股市,Ultragenyx Pharmaceutical Inc股票价格,Ultragenyx Pharmaceutical Inc股票交易,Ultragenyx Pharmaceutical Inc股票购买,Ultragenyx Pharmaceutical Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ultragenyx Pharmaceutical Inc(RARE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}